Skip to main content
Top

01-11-2022 | Osteoporosis | News

approvalsWatch

Abaloparatide recommended for EU approval to treat osteoporosis

Author: Claire Barnard

print
PRINT
insite
SEARCH

medwireNews: The EMA’s Committee for Medicinal Products for Human Use has recommended approval of abaloparatide, a parathyroid hormone-related protein, for treating osteoporosis in postmenopausal women at increased risk for fracture.

Abaloparatide works by increasing new bone formation through stimulation of osteoblastic activity, and has been shown to reduce the risk for new vertebral fractures in a placebo-controlled phase 3 trial.

The agent is administered as a subcutaneous injection and will be available as an 80 µg/dose solution. Reported adverse events associated with its use include arthralgia, back pain, dizziness, headache, hypercalciuria, hypertension, injection site reactions, nausea, and palpitations.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group

print
PRINT